Motley " 1 BIOTECH Wall Street Thinks Has MULTIBAGGER Potiental" (SRPT) link
1 Biotech Wall Street Thinks Has Multibagger Potential
By David Williamson and Brenton Flynn | More Articles | Save For Later
November 22, 2012 | Comments (0)
Sarepta (Nasdaq: SRPT ) Piper Jaffray has the company going up to somewhere between $60 and $80 in the near term and, staggeringly, suggests the potential for the stock to hit as high as $160 per share. In this video, Motley Fool health-care analyst David Williamson talks about how this relates to the company's tremendous results with its Duchenne muscular dystrophy drug eteplirsen, and how specific catalysts in the weeks and months to come could propel shares higher.